DexCom, Inc. - Common Stock (DXCM)
$88.32
0.00 (0.00%)
DXCM Stock Quote Delayed 30 Minutes
Should You Buy the 3 Worst Nasdaq 100 Stocks Since the Tech Sector Selloff?
The tech sector began selling off in July as investors abandoned former higher fliers, leaving these three as the worst Nasdaq 100 stocks.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
34.51B
PE Ratio
61.76
EPS
1.43
Volume (Avg. Vol.)
259
Day's Range
-
52-Week Range
$62.34 - $142.00
Dividend & Yield
N/A (N/A)
DXCM Stock Predictions, Articles, and DexCom, Inc. - Common Stock News
Get Your Money Out of These 3 Nasdaq Stocks by the End of July
Discover why these three Nasdaq stocks may be worth selling at their current price levels.
DXCM Stock Earnings: DexCom Beats EPS, Misses Revenue for Q2 2024
DXCM stock results show that DexCom beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
3 Breakthrough Medical Device Stocks to Invest In Now
Uncover the potential of leading medical device stocks boasting solid fundamentals and a promising future ahead.
Have $50K? 7 Stocks to Buy to Retire With $1 Million by 2034
These millionaire-maker stocks could turn a $50,000 investment into $1 million by 2034 if their growth trajectories remain intact.
Hype Hazards: 3 Stocks to Steer Clear of on Your Wealth-Building Journey
Learn why DexCom, TransDigm, and Datadog, three hyped stocks trading at rich valuations, may not be the best additions to your portfolio.
The 3 Best Diabetes Stocks to Buy in June 2024
There's less fear now about weight-loss drugs reducing the need for diabetes devices. Here are three diabetes stocks to buy.
DXCM Stock Earnings: DexCom Beats EPS, Beats Revenue for Q1 2024
DXCM stock results show that DexCom beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
The 3 Best Growth Stocks to Buy in January 2024
The best growth stocks to buy for 2024 with an impressive growth history and solid long-term tailwinds to support 30% EPS growth.
